Intercept shares more than doubled to $169 in premarket
trading on Thursday.
The company said it had stopped the trial after the committee
found that the drug, obeticholic acid, showed statistically
significant improvement in patients, compared with a placebo.
Nasdaq-listed Intercept said the committee made the
recommendation after reviewing liver biopsy data from about half
of the 283 patients enrolled in the trial.
The trial tested the drug in patients with non-alcoholic
steatohepatitis, a form of liver inflammation caused by a
build-up of fat.
(Reporting by Vrinda Manocha in
Bangalore; editing by Kirti Pandey)
[© 2014 Thomson Reuters. All rights
Copyright 2014 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.